Clinical science images at the ﬁrst presentation of RPE tear were used because tear border was the easiest to be demarcated. Visual acuity was transformed into logarithm of the minimum angle of resolution (LogMAR). Statistical analyses were done using PASW Statistics 18 (Predictive Analytics Software, V.18.0.0, IBM, Armonk, New York, USA). Demographic characteristics of the population are described with summary statistics, including frequency and percentage for categorical data. Continuous data are presented with mean 6 SD or with median. Correlation between ordinal and interval data (as in between RPE tear grade and LogMAR BCVA) was performed using Spearman’s rank order correlation coefﬁcient. p Value <0.05 was deemed as statistically signiﬁcant. Table 1 A summary of demographic characteristics RESULTS In all, 36 eyes of 33 patients were identiﬁed as having RPE tears. Demographic characteristics of these patients are shown in table 1. Among 33 patients, 12 were men and 21 were women. The mean age was 7668.3 (range 57e91) years old. The majority of patients (66.67%) had severe RPE tears, that is, grade 3 or 4 according to Sarraf et al.9 In the follow-up time, change in RPE tears grade is observed only in one patient (2.8%), that is, a case of self-healing RPE tear presented below. In our ﬁndings, there was no correlation between RPE tears severity grade and LogMAR visual acuity at the ﬁrst presentation (rs¼0.102, p¼0.553). Eighteen eyes (50%) received anti-vascular endothelial growth factor therapy prior to the RPE tear. Mean number of Patient no. RPE tear grade Age BCVA (LogMAR) at ﬁrst visit BCVA (LogMAR) at last visit Time after RPE tears (d) Total follow-up time (d) HRDs Subretinal mass at last follow-up 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 1212 Eye OS OD OS OD OS OD OS OD OD OS OD OD OD OS OS OD OD OS OD OS OD OD OD OD OS OD OS OS OD OS OD OD OS OD OD OD 2 3 3 3 4 3 4 2 3 4 1 2 3 4 2 4 4 3 2 2 3 4 1 4 4 2 3 4 1 1 4 4 4 4 1 4 BCVA, best corrected visual acuity; d, days; FAF, fundus autoﬂuorescence; HRDs, hyper-reﬂective dots; LogMAR, logarithm of the minimum angle of resolution; NA, not applicable; OD, the right eye; OS, the left eye; RPE, retinal pigment epithelium; rtPA, recombinant tissue plasminogen activator; SF6, sulphur hexaﬂuoride 20%. Br J Ophthalmol 2012;96:1211–1216. doi:10.1136/bjophthalmol-2012-301750 86 74 90 77 80 76 73 70 72 82 65 85 80 75 78 86 68 62 81 83 79 81 72 91 85 71 83 61 57 68 75 67 72 0.35 0.48 1.30 0.4 0.7 1.3 0.45 0.15 0.45 0.5 0.7 0.3 0.56 0.2 0.55 0.6 0.45 1 0.4 0.3 1.30 1.3 0.60 0.7 0.26 1 0.6 0.6 0.6 0.8 0.3 0.7 0.3 1.5 1 0.2 1.4 1.5 1.05 0.7 1.3 1.4 0.1 0.5 0.7 1.5 1.5 0.58 0.2 1 0.4 0.3 1.7 0.1 1.5 1.3 1.4 1.3 0.6 1 0.4 0.7 0.6 1.5 Therapy prior to RPE tear (no.) Bevacizumab (1) Bevacizumab (1) None Bevacizumab (4) Ranibizumab (3) None None None None Ranibizumab (3), Bevacizumab (1) Ranibizumab (3) Ranibizumab (2) None None Ranibizumab (3) None Ranibizumab (2) None None None Ranibizumab (3) rtPA+SF6 (1), ranibizumab (1) rtPA+SF6+ bevacizumab (2) None Ranibizumab (1) Ranibizumab (3) Ranibizumab (3) Ranibizumab (2) None None None None Ranibizumab (3) rtPA+SF6 (1), ranibizumab (5), bevacizumab (2) None None 1938 1681 882 325 330 222 212 1041 372 226 732 52 53 111 1165 128 104 109 333 670 593 32 77 895 110 663 317 158 1334 2092 1861 1911 329 425 1455 215 1344 1302 1302 1671 168 54 54 455 3405 337 1701 946 1262 819 925 1648 1648 231 992 2438 896 709 278 1996 810 FAF in RPE denuded area Dark Hazy hyperﬂuorescent Dark, patchy hyperﬂuorescent on the border Dark Dark Dark Dark Dark Dark Patchy hyperﬂuorescent Dark Dark Dark Dark Dark Patchy hyperﬂuorescent Dark Dark Dark Patchy hyperﬂuorescent Dark Dark Dark Dark Dark Dark Dark Dark Patchy hyperﬂuorescent Dark Dark Patchy hyperﬂuorescent Dark Dark Dark Dark No Yes No Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes No Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes No No Yes No Yes No No No No No Yes Yes Yes Yes No No Yes No No No No Yes No Yes Yes No No Yes No No